[ad_1]
Simon Clark, an expert in cell microbiology at the University of Reading, said: "The trial was able to show little effect on the speed at which patients cleared the virus, but this was not enough to increase their level of recovery from the disease.".
و: ضاف: "In simpler words, there were no clinical benefits for patients.".
The Indian researchers conducted the study on 464 adults with moderate cases of corona, who were transferred to hospitals across India between April and July.
The researchers randomly divided them into two groups: the first group received convalescent plasma twice, within a 24-hour interval, along with the best possible care, while the other group received only care.
After 7 days, the researchers said, the use of convalescent plasma appeared to improve symptoms such as shortness of breath and fatigue and led to higher rates of what is known as: "Passive change"In a sign that antibodies are neutralizing the virus, but this did not translate into a reduction in mortality or prevent the disease from reaching a severe stage.
Ian Jones, professor of virology at the University of Reading, said: "The low yield of convalescent plasma in this experiment is disappointing but not entirely surprising.".
He added that plasma would probably be worth it if given too quickly after infection with"COVID-19".
“>
After the experiment in India, results published Friday in the British Medical Journal showed that the convalescent plasma that carries the antibodies from those who recover from Corona to the infected “failed to reduce mortality rates or prevent access to symptoms. severe disease “.
The results, deduced from a study of more than 400 people infected with Coronavirus, represent a setback for a treatment method that US President Donald Trump described in August as a “historic development.”
The United States and India allow the use of convalescent plasma in emergency situations, and other countries, including Britain, are collecting donor plasma so that it can be used on a large scale if it is proven effective.
Simon Clark, an expert in cell microbiology at the University of Reading, Great Britain, said: “The experiment was able to show a negligible effect on the rate at which patients cleared the virus, but this was not enough to increase their level of recovery from the illness”.
He added: “In simple terms, there were no clinical benefits for patients.”
The Indian researchers conducted the study on 464 adults with moderate cases of corona, who were transferred to hospitals across India between April and July.
The researchers randomly divided them into two groups: the first group received convalescent plasma twice in a 24-hour interval along with the best possible care, while the other group received only care.
After 7 days, the researchers said, the use of convalescent plasma appeared to improve some symptoms such as shortness of breath and fatigue and led to higher rates of what is known as a “negative change,” a sign that antibodies neutralize. the virus, but this did not translate into a reduction in mortality or prevent the disease from reaching the dangerous stage.
“The low yield of convalescent plasma in this experiment is disappointing, but not entirely surprising,” said Ian Jones, professor of virology at the University of Reading.
He added that plasma is likely to pay off if given too quickly after infection with “Covid 19”.
[ad_2]
